Inqovi is a prescription medication used to treat anemia in adult patients with chronic kidney disease (CKD) who are on dialysis. It is a type of drug known as a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) [1].
How does Inqovi work?
Inqovi functions by stimulating the body's natural response to low oxygen levels. In individuals with CKD, this response is often impaired. Inqovi helps to boost the production of erythropoietin (EPO), a hormone that signals the bone marrow to create red blood cells, thereby increasing hemoglobin levels and improving anemia [1].
What are the potential side effects of Inqovi?
Common side effects reported with Inqovi include hypertension (high blood pressure), diarrhea, nausea, vomiting, headache, and nasopharyngitis (common cold symptoms) [1]. It is important for patients to discuss any concerns about side effects with their healthcare provider.
How is Inqovi administered?
Inqovi is taken orally, meaning it is swallowed as a pill. The dosage and frequency are determined by a healthcare professional based on the individual patient's condition and response to treatment [1].
When can Inqovi be prescribed?
Inqovi is indicated for adult patients with anemia due to CKD who are undergoing dialysis. It is not intended for use in non-dialysis CKD patients [1].
Where can I find more information about Inqovi's patent status?
Information regarding drug patents, including those for medications like Inqovi, can often be found on specialized databases. DrugPatentWatch.com provides resources for tracking drug patents and exclusivity periods [2].
What are other treatment options for anemia in dialysis patients?
Besides HIF-PHIs like Inqovi, anemia in dialysis patients is commonly treated with erythropoiesis-stimulating agents (ESAs) such as epoetin alfa and darbepoetin alfa. Iron supplementation is also frequently necessary to support red blood cell production [3].